D-0149-2020 Class II Terminated
FDA drug recall D-0149-2020 was initiated by Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center on Oct 9, 2019 and is designated Class II. Reason for recall: GMP Deviations: potential glass contamination The recall status is terminated (terminated Dec 1, 2020). Affected quantity: 615 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 30, 2019
- Initiation Date
- Oct 9, 2019
- Termination Date
- Dec 1, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 615 bags
Product description
PF-Fentanyl Citrate 2 mcg/mL* & Ropivacaine HCl 0.1% in 0.9% Sodium Chloride Injection-200 mL Total Dose: (400 mcg/200 mg)/200 mL, Rx Only Nephron 503B Outsourcing Facility 4500 12th St. Extension West Columbia, SC 29172 NDC: 69374-526-20
Reason for recall
GMP Deviations: potential glass contamination
Distribution pattern
Nationwide.
Code information
Lot: FR9002A Exp. 12/12/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0149-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026